Clopidogrel in the treatment of patients with ST-elevation acute myocardial infarction: state-of-art in 2013
https://doi.org/10.15829/1560-4071-2013-1-104-114
Abstract
This analytical paper presents the modern evidence on the dual antiplatelet therapy in ST-elevation myocardial infarction. A possible replacement of one dual therapy components – clopidogrel – with newer, more effective agents, such as ticagrelor and prasugrel, is discussed. For each of the latter medications, the existing evidence base is presented, together with the results of the studies comparing clopidogrel to ticagrelor and prasugrel. It is emphasized that only ticagrelor could potentially replace clopidogrel, and only as a part of the strategy based on primary percutaneous coronary intervention.
For other strategies, such as thrombolytic therapy, pharmacoinvasive approach, and impossibility of reperfusion, clopidogrel remains a nonreplaceable element of the dual antiplatelet treatment in patients with ST-elevation myocardial infarction.
About the Author
O. V. Averkov
O. M. Filatov City Clinical Hospital No. 15, Russian University of People’s Friendship, Moscow, Russia
Russian Federation
Russian Federation
References
1. Steg G., James D. K., Atar D. et al. Acute Myocardial Infarction in patients presenting with ST-segment elevation (Management of) European Heart Journal (2012) 33, 2569–619.
2. O’Gara P. T., Kushner F. G., Ascheim D. D., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013: published online before print December 17, 2012, 10.1161/CIR.0b013e3182742c84.
3. Sabatine M. S., Cannon C. P., Gibson et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352:1179–89.
4. COMMIT collaborative group. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005; 366: 1607–21.
5. James S., Akerblom A., Cannon C. P., et al. Comparison of ticagrelor, the first reversible oral P2Y (12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009; 157:599–605.
6. James S., Akerblom A., Cannon C. P., et al. Comparison of ticagrelor, the first reversible oral P2Y (12) receptor antagonist, withclopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009; 157:599–605.
7. Montalescot G., Wiviott S. D., Braunwald E., et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009; 373:723–31.
8. Wiviott S. D., Braunwald E., McCabe C. H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med.2007; 357:2001–15.
9. Sabatine M. S., Cannon C. P., Gibson C. M. et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI–CLARITY study. J Am Med Assoc (2005) 294:1224–32.
10. Mehta S. R., Tanguay J. F., Eikelboom J. W., et al. Double-dose versus standarddose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENTOASIS 7): a randomised factorial trial. Lancet 2010; 376:1233–43.
11. Kushner F. G., Hand M., Smith S. C. Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart
12. Association Task Force on Practice Guidelines. J Am CollCardiol. 2009; 54:2205–41.
13. Van De Werf F., Betriu A., Blomstrom-Lundqvist C. et al., Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29:2909–45.
Review
For citations:
Averkov O.V. Clopidogrel in the treatment of patients with ST-elevation acute myocardial infarction: state-of-art in 2013. Russian Journal of Cardiology. 2013;(1):104-114. (In Russ.) https://doi.org/10.15829/1560-4071-2013-1-104-114
Views:
524
Email this article 